Defining Treatment Goals and Mechanisms in EoE

In this episode, ‘Defining Treatment Goals and Mechanisms in EoE,’ the panelists explore how meaningful treatment response should be assessed and how available therapies address inflammation through different mechanisms. The experts describe a multidimensional approach incorporating symptoms, endoscopic appearance, and histology. They emphasize that dysphagia alone does not fully capture disease burden because patients may continue adaptive behaviors or experience persistent fibrostenotic symptoms despite histologic improvement.

Faculty discuss setting clear expectations with patients around objective targets. Histologic response and improvement in the EoE Endoscopic Reference Score can provide measurable evidence of disease control, while quality of life and the ability to return to previously avoided foods or social activities remain important patient-centered goals. The panel notes that these domains do not always improve in parallel, reinforcing the need to interpret them together.

The conversation then turns to mechanisms of treatment. Dupilumab targets signaling within the type 2 inflammatory pathway, including IL-4 and IL-13 signaling, whereas swallowed topical corticosteroids act locally on the esophageal mucosa to suppress inflammation. The faculty compare the systemic pathway-directed effects of biologic therapy with the local anti-inflammatory action of swallowed corticosteroids and note that a systemic biologic may also be relevant in patients with other type 2 inflammatory diseases.

The next episode in this series, ‘Applying REMODEL Findings to Esophageal Function in EoE,’ features the panelists examining esophageal distensibility and how structural and functional outcomes may add to conventional measures of disease control.